Popular Articles

Heart Charity Calls For The Government To Try Harder On Palliative Care
In response to the House of Commons Public Accounts Committee End of Life Care Report published Ruairi O"Connor, Head of Policy and Public Affairs at the British Heart Foundation (BHF) said:

Calming Parents Might Help Kids Cope With Anesthesia
The start of anesthesia can be distressing for children. Although antianxiety drugs can help keep kids calm, side effects exist. Non-drug methods offer alternatives, but a new review of studies finds that no single method shows a clear advantage in keeping the child calm and cooperative. The most commonly used tactic having the parent present while the child receives anesthesia medications does not appear to have any benefit.
News of the day
Urologist And Allergist Explore Link Between Allergies And Interstitial Cystitis
Allergy testing and treatment may offer a new therapeutic option for many patients with interstitial cystitis (IC). IC is a severely painful bladder condition affecting as many as 8 million women and 1.5 million men in the United States. Patients and the providers who treat them have long noticed a correlation between allergies and IC. Recently, a urologist and allergist in Louisville, Kentucky, began to explore the link between these two chronic ailments to provide patients with more effective treatment. The story of their discoveries is featured in the ICA Update, the quarterly magazine of the Interstitial Cystitis Association (ICA).
Health Insurance

Preventing Breast Cancer The Focus Of 2009-2010 Susan G. Komen For The Cure Promise Grants

One of the most important challenges in the cancer community today is whether people can, in fact, prevent their own cancers. Susan G. Komen for the Cure® is announcing millions of dollars in long-term grant funding to find out. The world"s leading breast cancer organization is now asking the scientific community for proposals for long-term research grants - some as large as $5 million - to study everything from the role of natural products to diets to breast cancer vaccines. "Prevention is a very hot issue these days, but clear enough scientific evidence to say that this diet, that behavior, or the elimination of this environmental agent significantly reduces your risk of breast cancer doesn"t yet exist. And we certainly don"t have a vaccine to prevent breast cancer," said Hala Moddelmog, Komen"s president and CEO. "Since our mission is to end breast cancer forever, we consider prevention and vaccine research absolutely critical, and we"re willing to invest significant sums to get these answers." The research will be funded through Komen"s unique Promise Grants: multi-year, multi-million dollar projects geared to answer the toughest questions in breast cancer science today. Introduced in 2008, Promise Grants require collaboration across a wide range of disciplines - scientists, medical professionals, caregivers, public health specialists and advocates - who normally may not work together. These teams conduct research with the highest potential to deliver treatments for breast cancer more quickly and for this new Promise Grant to find ways to prevent breast cancer. "Komen"s mission has always been to find cures for breast cancer, which to this point has involved hundreds of millions of dollars and three decades of research into understanding the disease and developing treatments that are saving lives," said Diana Rowden, vice president of Health Sciences. "It"s absolutely critical for us to work on strategies to prevent breast cancer entirely, or at least pinpoint the environmental and lifestyle issues that may contribute to breast cancer. We know this research will get us closer." Komen"s $450 million in research funding since its founding in 1982 has touched every major development in breast cancer treatments during the past 27 years. In the last three years alone, Komen has invested more than $230 million in research projects in the U.S. and internationally. About the Request for Applications These upcoming grants will run from three to five years with amounts up to $5 million. Applications for the grants will be accepted until July 15, 2009. In order to be considered for funding, researchers must be able to prove their prevention approach is worthwhile and must start testing it on humans before the five-year grant expires. The grants are aimed especially at novel approaches to breast cancer prevention. Grant applicants should also describe how their findings from early phase trials will lead to more advanced testing and ultimately to a prevention for breast cancer. Research designed to prevent breast cancer from recurring will not be considered for the 2009-2010 Promise Grants, but these grants may be used to support drug formulation, dietary and/or behavioral formulas, or previously untested novel methods. Komen for the Cure will be accepting applications from U.S. and international researchers but they must work for nonprofit institutions or organizations. The grant allows for the involvement of industry partners, however they can not be reimbursed for any fee or profit. Interested applicants can visit http://ww5.komen.org/researchgrants/grantprograms.html for details. The anticipated start of funding for these prevention Promise Grants is May 2010. Susan G. Komen for the Cure®


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):